Buoyed By US Tax Reform, Merck Plans $12bn In Capital Investments
Executive Summary
Keytruda had a great year in 2017 with $3.8bn in sales, but some Merck investors would like to see more M&A activity to bolster the company's pipeline, relaxing dependency on the blockbuster PD-1 inhibitor. However, the company revealed $12bn in capital investments to support planned growth.
You may also be interested in...
Pharma Q1 Results Preview: Merck & Co, Pfizer, Gilead, Novo Nordisk, Teva, Celgene
Merger appetites and competitive dynamics will continue to be assessed as investors grill the next round of biopharma companies presenting first quarter sales and earnings. Gilead and Pfizer will be particularly pressed on deals.
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
Merck came out ahead in the immuno-oncology combination showdown at AACR, with a strong overall survival benefit for Keytruda/chemo in the Phase III KEYNOTE-189 study in first-line NSCLC. The data were seen as practice-changing, but Bristol's CheckMate-227 trial of Opdivo/Yervoy failed to impress in the same way.
How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says
As pharma invests its bounty from last year's tax reform in stock buybacks, capital improvements and other investments, Sen. Cory Booker issues a report suggesting companies should lower drug prices instead, but does not offer recommendations for how that might be done.